Kornimate/medical-research-clean huggingface dataset:
prevalance of helicobacter pylori infection in chonic kidney diseased patient admitted to luxor medical complex

Conditions: Chronic Kidney Diseases

Summary: detect prevalence of helicobacter pylori infection in chronic kidney diseased patient admitted to luxor medical complex and possible role of helicobacter pylori in pathogenesis of chronic kidney diseased patient of unknown etiology

helicobacter pylori bacteria is the main pathogenic organism that settles on the gastric mucosa of more than half the human population around the world, with more prominence in the developing countries. h. pylori had been found to be the main factor in acute and chronic gastritis, peptic ulcer diseases, and in most cases gastric malignancy. beside to some extra gastro-intestinal diseases. such as cardiac, pulmonary, renal and hematological diseases. another study showed a significant higher proteinuria in h. pylori infected patients compared to non-infected individuals. helicobacter pylori is a gram-negative bacterium infecting both children and adults. it is the most common human chronic infection, causing gastrointestinal diseases such as gastric malignancies, gastritis, and ulcerative diseases. h. pylori can also be involved in other non gastrointestinal infections such as diabetes and metabolic syndrome, heart disease, hematologic disorders, cancer, and chronic kidney disease (ckd) as well as chronic renal failure (crf). some chronic renal failure patients who have received hemodialysis for long periods complained of gastrointestinal troubles. it has been postulated that high urea concentration makes the gastric mucosa of these patients more susceptible to h. pylori colonization. previous observations in different countries reported the prevalence of h. pylori infection among patients with crf ranging between 20 and 60%, and h. pylori infection can contribute to progressive renal dysfunction resulting in ckd development. in patients without established gastric dysfunction, the presence of h pylori infection was associated with increased risk for chronic kidney dusease however, patients with both atrophic gastritis (ag) and helcobacter pylori infection appeared to be at decreased risk for chronic kidney disease compared with control participants. for the h. pylori-positive patients with peptic ulcer, h. pylori infection may be a risk factor resulting in kidney damage and h. pylori eradication probably benefits to kidney damage relief and chronic kidney disease prevention.

Eligibility criteria:
inclusion criteria: * all patients aged \>18 years old with chronic kidney disease of different etiology based on clinical examination, laboratory investigations and imaging exclusion criteria: 1. patients aged ≤18 years old. 2. overloaded patients 3. patient with acute kidney injury 4. patients with other git disease 5. pregnant female 6. patient taking aspirin, nsaid, steroid or antibiotic 7. presence of malignancy
accute effect of b-turmactive both on mild and moderate knee pain on healthy volunteers

Conditions: Knee Injuries; Inflammation Knees

Summary: the goal of this study is to assess the short (acutte) effect of b-turmactive (one week treatment) both on mild/moderate knee pain

join pain is a common cause of consultation in primary health care in the adult population. indeed, people who suffer knee pain, mostly due to osteoarthritis, require analgesic treatment, often with some secondary effects. therefore, the research to find a natural and efficient product to reduce knee pain in a short period of time, facilitating recovery after exercise and without side effects have an interest both for industry and for the general population. b-turmactive is an extract of curcuma longa mixing two fractions in a single product: a) soluble fraction free-curcuminoids but rich in polysaccharides and b) curcuminoids fraction with cyclodextrin. both fractions plus vitamin c are b-turmactive. previous preclinical studies suggest that b-turmactive could exert an acute effect in healthy people that suffer mild or moderate knee pain and, furthermore could reduce inflammation process. therefore, the goal of this study is to assess the short (acute) effect of b-turmactive (one week treatment) both on mild/moderate knee pain

Eligibility criteria:
inclusion criteria: * men and women between 30 and 65 years old. * score between 15-25 out of 50 within womac pain subscale * signed informed consent. exclusion criteria: * people who take concomitant drug or supplements (multivitamins) that could interfere with the product under study. * people who suffer froma arthritis of the knee. * people who take more than two analgesic drugs and/or anti-inflammatory for more than three months. * people who have a history of surgery or trauma affecting the knee. * people with gluten sensitivity and/or allergy to gluten and sulphites (the placebo containing yeast). * people with anemia (haemoglobin ≤ 13g/dl in men and ≤ 12g/dl in women). * people with bmi ≥ 30 kg / m * women pregnant or breastfeeding. * women with menopausal suffering from osteoporosis. * people with liver abnormalities (alt, ast), kidney (creatinine) or other muscular issues (creatine kinase). * people with neurological disorders. * people who have participated in a clinical trial or intervention study the last 30 days prior to inclusion in the study. * people unable to follow the guidelines of the study. * people who not signed the informed consent.

Keywords: knee-pain, curcuma, inflammation
secondary data analysis of patients at risk for ckd to inspect ckd prevalence, diagnosis rates, diagnostic behaviour, treatment patterns and patient characteristics

Conditions: Chronic Kidney Diseases

Summary: this study is a national secondary data analysis to determine the prevalence of diagnosed and undiagnosed ckd in german primary care offices in a patient population at high risk for the development and progression of ckd. furthermore, it addresses the question of how ckd screening, monitoring and treatment of these patients is conducted within the german primary care setting.

the study does not attempt to test any specific a priori hypothesis; it is descriptive only. data on general patient characteristics, health insurance details, participation in disease management programs and/or family doctor-centred care, diagnoses, prescriptions, surgeries, and procedures, used billable services and laboratory test results are documented during daily routine by the physician. the data used in this setting are part of routine visits, dating back a maximum of 24 months from the date of first data transfer within the study period.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years at start of the patient´s observation period 2. having at least one of the following diseases (based on the documented icd-10 code): * type 1 diabetes * type 2 diabetes * hypertension * cardiovascular disease, including: 1. coronary and/or other atherosclerosis 2. myocardial infarction 3. heart failure 4. peripheral arterial disease 5. arrythmia 6. stroke 3. having at least one year (52 weeks) of observation period exclusion criteria: na

Keywords: chronic kidney diseases ckd sglt2i
beneficial effect of xylose consumption on postprandial hyperglycemia

Conditions: Postprandial Hyperglycemia

Summary: the present study determined the effect of xylose consumption on postprandial hyperglycemia in normal (n=25) and hyperglycemic subjects (n=50).

in this double-blind crossover designed study, participants were randomly assigned to consume a sucrose drink (control, sucrose 50g + deionized water 100g) or a sucrose drink additionally containing 5 g (test 1, sucrose : xylose = 10:1), 3.33 g (test 2, sucrose : xylose = 15:1) or 2.5 g (test 3, sucrose : xylose = 20:1) of d-xylose with a week interval.

Eligibility criteria:
inclusion criteria: 1) healthy subject or impaired fasting glucose (fasting serum glucose between 100 and 125 mg/dl) exclusion criteria: 1. history of taking an insulin-injection or oral hypoglycemic agents 2. evidence of alcohol abuse or alcoholism 3. pregnancy or breast feeding 4. chronic gastrointestinal disorder 5. seriously abnormal liver or renal function 6. an occupation at risk of death when hypoglycemia occurs

Keywords: xylose prediabetes postprandial hyperglycemia glucose
efficacy and safety of empagliflozin (bi 10773) in patients with type 2 diabetes and renal impairment

Conditions: Diabetes Mellitus, Type 2; Renal Insufficiency

Summary: this study will investigate the efficacy and safety of the bi 10773 in type 2 diabetic patients with renal impairment in order to provide these data for approval for bi 10773 as an antidiabetic agent by regulatory authorities.


Eligibility criteria:
inclusion criteria: 1. diagnosis of type 2 diabetes mellitus prior to informed consent and an estimated glomerular filtration rate of \<90 ml/min. 2. male and female patients on diet and exercise regimen who are pre-treated with any antidiabetic therapy and are on the maximum tolerated dose which has been unchanged for 12 weeks prior to randomisation. 3. hba1c greater than or equal to 7.0% and less than or equal to 10.0% . 4. aged 18 years or above. 5. body mass index less than or equal to 45 kg/m2 exclusion criteria: 1. uncontrolled hyperglycaemia defined as \>13.3 mmol/l after an overnight fast during placebo run-in. 2. impaired renal function, defined as an estimated glomerular filtration rate \<15 ml/min. 3. renal impairment requiring any form of chronic dialysis. 4. requiring acute dialysis within three months prior to informed consent. 5. renal transplant recipient. 6. myocardial infarction, stroke or transient ischemic attack within three months prior to informed consent. 7. indication of liver disease. 8. bariatric surgery within the past two years. 9. medical history of cancer. 10. blood dyscrasias or any disorders causing hemolysis or unstable red blood cell. 11. contraindications to pre-existing background antidiabetic therapy. 12. treatment with anti-obesity drugs. 13. current treatment with systemic steroids or change in dosage of thyroid hormones within six weeks prior to informed consent or any other uncontrolled endocrine disorder except type 2 diabetes. 14. pre-menopausal women who are nursing or pregnant or are of child-bearing potential and are not practising an acceptable method of birth control.
sit-to-stand training in stroke patient

Conditions: Stroke

Summary: background: it is unknown whether the self-initiated sit-to-stand training with assistive device is effective to regain the independence of sit-to-stand in stroke patients. objective: to compare the effectiveness of self-initiated sit-to-stand training by assistive device, with manual sit-to-stand training. design: parallel randomised controlled and assessor blinded trial between jan 2015 and may 2018. randomisation was performed by drawing lots to allocate treatment to patient. setting: a rehabilitation hospital in hong kong participants: 69 patients in medical wards with unilateral hemiparetic stroke. 52 patients fulfilled the study requirements. intervention: ten sessions of intervention with conventional physiotherapy program followed, by self-initiated sit-to-stand training with assistive device, or by manual sit-to-stand training. main outcome measure: number of patients regained the independence of sit-to-stand, sit-to-stand test from the balance master® and five-repetitions sit-to-stand test. results: 69 patients (intervention n=36; control n=33) were randomized (mean age 69.8 (sd, 10.6), mean post stroke days 18.6 (sd 16.0)) for intention to treat analysis. 17 patients were excluded because of dropout before 10 sessions of training, leaving 52 (n=26; n=26) patients for per protocol analysis. 18 patients in intervention group and 10 patients in control group had regained the independence of sit-to-stand (phil and cramer's v: -0.31 and 0.31). the patients in intervention group were faster to complete the five-repetition sit-to-stand test than the control group (32.7 secs (sd, 1.93) v 48.4 secs (sd, 6.8); 95% confidence interval, -30.8 to -0.7; p\<0.05). no adverse side effects occurred during and after the training across groups. conclusions: self-initiated sit-to-stand training by assistive device can help more stroke patients regain the independence of sit-to-stand.


Eligibility criteria:
inclusion criteria: * first episode of unilateral stroke with hemiparesis, * able to understand and follow simple verbal instructions, * able to sit unsupported for at least two minutes * require lifting assistance to stand up from a 18 inches high plinth exclusion criteria: * severe pain in the lower extremities when weight bearing or performing movement * any other acute comorbid diseases such as unstable angina, recent myocardial infarction * unstable medical / psychological condition
cross-cultural adaptation, reliability and validity of the turkish version of the headache impact questionnaire

Conditions: Headache; Headache Disorders; Headache, Migraine; Headache, Tension; Headaches Chronic; Headaches Muscular

Summary: the purpose of this study was to investigate cultural adaptation, reliability and validity of the turkish version of the headache impact questionnaire (hiq).

the episodic nature of migraine attacks presents a number of difficulties in characterizing disease severity. there are differences in the severity, frequency and intensity of attacks and the general effect of the disease in individuals. information about any particular attack is not sufficient to characterize the overall severity of the disease. accordingly, the headache impact questionnaire (hiq) was developed to evaluate the headache experience over a period of time instead of any headache. developed to measure the impact and quality of life of individuals suffering from headache, hıq evaluates the frequency and duration of headache, the degree of pain severity, daily life activities, disruptions in work or school life, the influence of the individual's leisure activities and other symptoms that may occur. hiq consists of 16 items and the higher the score shows the seriousness of the impact. the study is planned with 80 individuals with complaint of headache. after questioning the sociodemographic characteristics of the individuals, the patients will be asked to fill in hiq, migraine disability assessment questionnaire, headache impact test-6 and short form-36.test-retest will be re-applied to those of the same individuals who can be reached after 1 week. the results will be analyzed using the spss version 22.0 computer package program.

Eligibility criteria:
inclusion criteria: * diagnosed with any type of headache, * have a chronic headache. exclusion criteria: * having a cognitive and neurological disorders.

Keywords: headache reliability validity cross-cultural adaptation
effect of very-low calorie diet and synbiotic supplementation in gut microbiota (pronokal method)

Conditions: Weight Loss; Inflammation

Summary: the present study aimed to investigate the changes produced in gut microbiota by a very-low-calorie-ketogenic diet followed by a low calorie diet, whether the use of synbiotics is able to modulate gut microbiota diversity and composition and its association with gut permeability and inflammation

all participants followed a very-low-calorie ketogenic diet according to a commercial weight loss program (pronokal method), which includes lifestyle and behavioural modification support. this method is based on high-biological-value protein preparations which contained 15 g protein, 4 g carbohydrates, 3 g fat and 50 mg docosahexaenoic acid, and provided 90-110 kcal. the study was divided in two phases. the first phase consists of a very-low-calorie ketogenic diet (600-800 kcal/day), low in carbohydrates and lipids. throughout this ketogenic phase, supplements of vitamins and minerals such as k, na, mg, ca and omega-3 fatty acids were provided. in this study the ketogenic step was maintained for 2 months. then, the patients started a low-calorie diet (800-1500 kcal/day) which lasted two months. during the first phase consisting of a very-low-calorie ketogenic diet, subjects were randomly divided into two groups, the treatment group who received synbiotic supplementation as capsules, a complex of b. lactis, lactobacillus rhamnosus, b. longum es1 and prebiotics fiber (synbiotic 1) and the control group who received a placebo. during the second phase consisting of a low-calorie diet, the treatment group received synbiotic supplementation as capsules consisting of b. animalis subsp. lactis and prebiotics fiber (synbiotic 2) (synbiotic1 + synbiotic 2 group), while the control group was divided into two groups: one continued receiving a placebo (control group) whilst the other group received synbiotic 2 (placebo + synbiotic2 group).

Eligibility criteria:
inclusion criteria: * body mass index ≥ 30 kg/m2 * stable body weight in the previous 3 months exclusion criteria: * diabetes mellitus * obesity induced by endocrine disorders or by drugs * gastrointestinal disorders * use of antibiotics, probiotic or prebiotic agent which could modify microbiota in the previous 3 months * severe depression or any other psychiatric disease * abuse of narcotics or alcohol * severe hepatic insufficiency * any type of renal insufficiency or gout episodes * neoplasia * previous events of cardiovascular or cerebrovascular disease * renal lithiasis * uncontrolled hypertension and hydroelectrolytic alterations * females with child-bearing potential, who were pregnant, breast-feeding, intending to become pregnant

Keywords: microbiota obesity
home-based symptom monitoring: its impact on cancer care team behaviors and patient outcomes

Conditions: Cancer; Solid Tumor; Hematologic Malignancy

Summary: the primary research objective of this protocol is to evaluate the impact of integrating a home-based symptom monitoring system in the day-to-day care of cancer patients in community settings on the frequency of supportive symptom interventions, symptom severity, and quality of life.

patients will be randomly assigned to one of two groups. one group will be offered an internet assisted home-based symptom reporting system cancer symptom monitor (csm) for a twelve-month study period. patient and care team evaluations will be measured using quantitative and qualitative methods (via focus groups). the second group will receive "standard care" without home-based symptom monitoring. both groups will be evaluated at baseline, 1, 2, 3, 6, 9, \& 12 months, for symptom levels and overall quality of life during the twelve-month study period.

Eligibility criteria:
inclusion criteria: 18 years old or older diagnosis of solid tumor or hematologic malignancy starting active treatment (chemotherapy or hormonal therapy) must be able to give informed consent \& consent to use the cancer symptom monitor - exclusion criteria: inability to give informed consent life expectancy of less than 3 months subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.

Keywords: cancer symptom management supportive symptom interventions symptom severity quality of life home-based symptom monitoring
cough in reduced true vocal fold mobility

Conditions: Unilateral Vocal Cord Paresis; Unilateral Vocal Cord Paralysis

Summary: this project is a first attempt to assess cough airflow dynamics and true vocal fold (tvf) adduction and abduction angles during voluntary cough to examine the effects of changes in glottal closure due to reduced mobility of one true vocal fold. the hypothesis of this study is that the incomplete glottal closure due to reduced vocal fold mobility will result in changes in true vocal fold adductory and abductory angles during cough and will result in changes to voluntary cough airflow parameters. this study results will contribute to the existing knowledge of the laryngeal contribution to cough airflow dynamics.

the study investigators will consecutively recruit 30 adults diagnosed with vocal fold insufficiency due to reduced mobility of one true vocal fold. a questionnaire will be used to collect participants' information. demographic information such as age, gender, race/ethnicity, height, weight, and a major complaint (dysphonia and/or dysphagia) and medical history information determining the eligibility for participation will be collected from the participant. participant's medical and surgical history specifically related to the diagnosis and the etiology of reduced vocal fold mobility will be obtained from the participant's medical record. videolaryngoscopy will be performed as part of standard clinical care. vocal fold image and cough airflow will be recorded simultaneously during voluntary cough production with the flexible endoscope in nasopharynx. a second part of the study will include spirometry and expiratory muscle strength assessments. video images of the vocal fold movement during vowel phonation and cough production will be recorded and stored on a cd for later analysis. the cough airflow recordings will be displayed, stored, and analyzed using labchart software for windows.

Eligibility criteria:
inclusion criteria: 1. age between 40 and 75 years. 2. glottal insufficiency secondary to reduced tvf mobility confirmed with the endoscopic evaluation performed by an otolaryngologist. 3. the ability to provide informed consent. 4. no history of chronic obstructive pulmonary disease, lung cancer, and/or lung transplant. 5. no history of neurodegenerative disease such as parkinson's disease, multiple sclerosis (ms), amyotrophic lateral sclerosis (als), or progressive supranuclear palsy (psp), alzheimer's disease, or dementia. exclusion criteria: 1. chest infection within one month prior to the study participation. 2. history of the adverse reaction associated with laryngoscopy.
measurement of hemodynamic responses to lower body negative pressure

Conditions: Hypotension and Shock

Summary: this study will be collecting data on participants undergoing lower body negative pressure (lbnp) to simulate progressive blood loss. the goal of the study is to collect data to allow for development of an algorithm with machine learning to predict blood pressure responses to hypovolemia by analyzing the arterial waveforms collected during lbnp.

death from exsanguination continues to be a major problem in combat casualty care and the care of civilians subjected to trauma. the ability to detect significant blood loss using traditional vital signs (heart rate, blood pressure) is marginal due to a variety of compensatory mechanisms that maintain blood pressure in the face of marked reductions in circulating blood volume. along these lines, it is critical to develop monitoring devices and algorithms to non-invasively assess central blood volume in humans for the purposes of facilitating more timely interventions. the standard way to simulate hemorrhage in humans is to use lower body negative pressure (lbnp). in this technique, the lower body of a supine volunteer is enclosed in an airtight container while suction is applied to cause venous pooling in the legs and reduce central blood volume. this technique generates many physiological adaptations that are similar to that observed during blood loss studies in animals and human volunteers. thus, the purpose of this study is to obtain data for use in developing monitoring technology to detect hemorrhage and other surrogate markers of central blood volume in humans.

Eligibility criteria:
inclusion criteria: 18-55 year of age non-smoker no history of hypertension no history of diabetes no history of coronary artery disease no history of neurologic disease exclusion criteria prescribed medications other than birth control inability to lie flat for two hours bmi \> 30 kg/m2